Please provide your email address to receive an email when new articles are posted on . The FDA expanded linaclotide approval for IBS-C to include children aged 7 years and older. Linaclotide is now ...

Many Medicare Part D plans cover Linzess, but out-of-pocket costs can vary because private insurance companies manage these plans. Linzess is an expensive medication with no generic alternatives ...

The FDA approved linaclotide (Linzess) capsules to treat irritable bowel syndrome with constipation (IBS-C) in children age 7 years and older, the agency announced Wednesday. The decision makes the ...

The FDA has approved linaclotide (Linzess) for children aged 7 years or older with irritable bowel syndrome with constipation (IBS-C), making it the first approved treatment for pediatric IBS-C. The ...

FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...

If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 Submission is based on positive Phase 3 study data ...

The U.S. Food and Drug Administration on Wednesday approved Linzess (linaclotide), developed by Ironwood Pharmaceuticals (IRWD) and AbbVie (ABBV), for children with irritable bowel syndrome with ...

・The recommended dosage for pediatric patients seven years and older with IBS-C is 145 mcg orally once daily, the FDA said. ・Linzess is already approved for the treatment of adult patients with the ...